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Objective: In its fiscal year (FY) 2015 final rule, the Centers for Medicare & Medicaid (CMS) 
required reporting of tobacco treatment quality measures as part of the Inpatient Psychiatric 
Facilities Prospective Payment System (IPF PPS).  This study evaluates the impact of that policy 
at a large academic medical center that opted to improve performance as it implemented 
reporting measures.  
 
Methods: Electronic medical record data were collected retrospectively for all inpatient 
psychiatric admissions one year prior to and following implementation of the rule (Jan 1st 2014 
to December 31st 2015). Data from admissions (2014=292; 2015=338) were analyzed to 
determine changes in the provision of tobacco treatment including the proportions of patients 
screened for tobacco use, receiving tobacco cessation counseling, and receiving tobacco 
cessation medication(s).  
Results: Compared to the year before the CMS rule, screening for admissions increased 
significantly (85% vs 97%;  < .001).  Even greater pre-post rule increases were found for 
referral to cessation counseling (4.3% vs. 73.8%;  < .001), reciept	of	counseling	 (7.8% vs. 
67.1%;  < .001)	and referral for cessation medication (32% vs. 68.4%;  < .001).	 Even 
though statistically non-significant, the number of tobacco users who actually received 
medications increased markedly between 2014 and 2015 (24.3% vs. 34.9%;  = 0.064). Gains 
in screening, referral, and treatment did not differ by psychiatric diagnosis.  
Conclusions: The IPFQR Program resulted in dramatic changes in tobacco-related screening, 
documentation, and cessation treatment for psychiatric inpatients. Should CMS link prospective 
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Tobacco use continues to be one of the leading causes of preventable death in the United 
States with an estimated 480,000 annual deaths attributable to smoking.(1) Overall, patients with 
mental illness account for 44.3% of the annual tobacco-consumption in the U.S. (2)  As a result, 
nearly half of the annual deaths attributable to smoking occur in patients with mental illness (3) 
and life expectancy for patients receiving public mental health treatment is 25 years below that 
of the general population, with heart disease as the leading cause of death.(4) An estimated $168 
billion dollars are spent annually in direct care for smoking-related illnesses, half of which is 
paid through Medicare and Medicaid (5), which are the principle sources of health care coverage 
for people with severe mental illness (SMI) (6, 7) 
The prevalence of smoking in the United States continues to decrease annually—in 2014 
the estimated prevalence rate was 16.8% compared to 20.9% in 2005. (8) This is in part due to 
increasing rates of cessation, however, among patients with mental illness prevalence rates have 
remained stagnant.(9, 10) Compared to the general population, patients with mental illness have 
2.7 times the odds of smoking, up to 5.3 times in patients with schizophrenia.(2, 11) Smoking 
rates differ between psychiatric diagnoses and can vary from 34.9% for patients with anxiety 
disorders to 59.1% for patients with schizophrenia, and upwards of 71-92% in patients with 
substance abuse disorders.(12-15) Despite the high prevalence of tobacco use among people with 
SMI, the high rates of morbidity and mortality, and the high health care costs for treating 
tobacco-related illnesses, tobacco use remains ignored or even encouraged in mental health 
settings. (16) 
Tobacco use interferes with the clinical management of psychiatric illness. Polycyclic 
aromatic hydrocarbons found in cigarette smoke alter the pharmacokinetics of psychotropic 
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medications via induction of cytochrome P450 enzymes, reducing plasma concentrations of 
tricyclic anti-depressants and antipsychotics. (17-19)  Patients’ tobacco use is typically poorly 
addressed during psychiatric inpatient care.(20, 21) However, patients who receive tobacco 
treatment during psychiatric hospitalization have been shown to have a lower likelihood of being 
discharged against medical advice and have a lower likelihood for rehospitalization when 
treatment is continued post discharge.  (20, 22) 
The history of tobacco use in patients with mental illness is complicated by a myriad of 
stakeholders. Tobacco marketing efforts routinely targeted homeless populations and patients 
with mental illness through discounted promotions, cigarette donations to hospitals and shelters, 
as well as financial grants to organizations that served these populations. (23) The tobacco 
industry was also complicit in subverting efforts of researchers and health organizations to warn 
the public about the effects of tobacco use.(24-27) The tobacco industry also rallied allies to 
oppose the introduction of tobacco-use disorder as a diagnosis in the Diagnostic Statistical 
Manual (DSM-III). (28) This was the first time that nicotine dependence was classified as a 
medical condition, changing the paradigm of smoking and smoking cessation from being viewed 
solely as an issue of self-will.  
State and local ordinances combined with healthcare policy changes, have changed the 
smoking culture in the U.S. Cigarette use has been all but removed from public spaces with only 
Southern states still lacking in comprehensive indoor smoking bans.(29)  A 2006 study utilizing 
NHANES data found that public health initiatives in the U.S. led to a 70% reduction in serum 
cotinine levels among non-smokers between 1988 and 2002.(30) 
The Joint Commission (JC) has been instrumental in implementing changes in healthcare 
to address tobacco-use and treatment.  In 1992 the JC banned indoor smoking for all accredited 
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hospitals. This was the first industry-wide workplace smoking ban aimed at reducing smoking in 
hospital employees and resulted in increased smoking cessation rates for workers employed by 
accredited hospitals. (31) Despite the Joint Commissions efforts, indoor smoking policy did not 
extend to psychiatric facilities/units. In response to public outcry over banning smoking in 
psychiatric units, with advocates citing patient rights, the JC policy exempted psychiatric units 
from the indoor smoking ban. (32, 33) 
The Joint Commission additionally established performance measures aimed at 
improving tobacco treatment for hospitalized patients. In 2012 updated JC measures improved 
upon those initially set in 2004 which impacted only patients hospitalized due to myocardial 
infarction, congested heart failure or pneumonia, a rather select subpopulation, and did not 
require hospitals to provide evidence based tobacco-use counseling or cessation medications. 
(34) Reported smoking cessation advice/counseling rates under the 2004 measures varied vastly 
between public, non-profit and private hospitals, with minority groups and Medicaid patients 
being less likely to receive cessation advice or counseling.(35)    
Hospitalization is a significant life event for patients and has been shown to be a unique 
opportunity for health care providers to engage smokers in cessation treatment. Cessation 
counseling initiated during hospitalization, combined with one month of support post-discharge, 
has been shown to increase the odds of quitting by as much as 65%. (36)  
Smoking cessation treatment in patients with mental illness has lagged in comparison to 
the general population due to issues beyond that of patient rights. Tobacco use as a form of harm 
reduction is a view that has perpetuated the smoking norm in the behavioral health field. (37) 
Mental health staff have been apprehensive about implementing smoking bans due to concerns 
that such bans would only exacerbate psychiatric symptoms, and adversely affect the therapeutic 
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relationship between staff and patients as cigarettes have been used to reinforce behaviors and 
build rapport with patients.   (38-40) State psychiatric facilities have made progress in 
implementing smoking policies with 83% of state facilities prohibiting smoking as of 2011 
compared to 48% in 2008. (41) Contrary to initial concerns, implementation of smoke free 
policies in psychiatric facilities has shown to decrease the number of behavioral incidents related 
to smoking and improve interactions between staff and patients. (42-44) 
As part of the Inpatient Psychiatric Facilities Quality Reporting (IPFQR) Program, in 
2015 the Centers for Medicare & Medicaid Services (CMS) implemented new quality reporting 
measures targeting tobacco use screening and tobacco use treatment for all inpatient psychiatric 
facilities receiving Medicare funds. Tobacco-use screening (TOB-1) assesses the number of 
patients screened within three days of admission for reported tobacco use in the last 30 days.(45) 
TOB-2 assesses the proportion of tobacco users who, within 3 days of admission, received or 
refused tobacco cessation counseling, and received or refused FDA approved cessation 
medications.(45) TOB-2 is, in effect, a measure of whether tobacco treatment was offered.   
TOB-2a measures the proportion of all identified tobacco users who actually received cessation 
counseling and/or medications. (45) 
These tobacco measures were implemented in an effort to address the health disparity 
that exists in the mentally ill population, and to provide consumers with the information needed 
to make an informed decision on where to seek care. (46)   Psychiatric facilities that fail to report 
required measures face a 2% decrease in annual payment updates. With an estimated 1,626 
inpatient psychiatric facilities nationwide participating in the IPFQR program, and an estimated 
total of 904,056 cases reported on each year, this policy has potential to make a substantial 
impact on tobacco treatment among patients with mental illness. (46) At present, however, 
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funding penalties are tied solely to whether or not a given facility reports these quality measures, 
not to how the facility performs on the measures. 
Although not required by the rule change, the University of Kansas Hospital (KUMed) 
also opted to enact a number of policy and practice changes designed to enhance not only 
reporting but also performance on the tobacco measures. These included brief trainings on the 
CMS tobacco measures with all psychiatric residents at the beginning of their hospital rotation, 
daily monitoring of tobacco screening and treatment delivery for all new admissions increased 
coordination with unit staff to ensure tobacco measures were met within the specified time 
period. Within the electronic medical record (EMR), a link from the nursing flow sheet was 
created to initiate an automatic referral to UKanQuit, KUMed’s tobacco treatment service.  
The purpose of this study is to examine the impact of new CMS tobacco reporting 
measures on the screening and provision of tobacco cessation counseling and cessation 
medications for inpatient psychiatric smokers. The study takes place in an academic medical 
center that opted to enhance performance on the measures as it created mechanisms for better 
reporting. Hence, this study describes the changes in documentation made in order to capture the 
new measures, changes in clinical practice in order to improve performance on these measures, 
and the resultant changes in screening and service delivery. As such, this represents an analysis 
of a hospital that moved beyond the letter to the spirit of the new rule.  By doing so, the hospital, 
and this report, foreshadows the potential improvements in treatment quality that could be gained 








The reporting period for the new tobacco measures began on January 1, 2015.  In order to 
evaluate its impact on hospital practices, we retrospectively abstracted electronic health record 
data on all admissions to KUMed’s psychiatric unit the year prior to and the year immediately 
following policy implementation (January 1st 2014-December 31st 2015). We cleaned the data 
set, imported it to SAS, and examined pre- and post-policy changes in the rates of screening, 
referral, and delivery of cessation counseling and cessation medications for tobacco users. We 
also described differences by diagnosis.  This study was approved by the University of Kansas 
Human Subjects Committee. 
Setting  
 KUMed is a 550 bed academic center with a 32-bed inpatient psychiatric unit. KUMed 
has a dedicated tobacco treatment service, UKanQuit, which provides evidence-based tobacco 
treatment for referred patients. UKanQuit treatment consists of bedside smoking cessation 
counseling, recommendations for cessation medications both inpatient and on discharge, and 
referral to the state quitline for post-discharge counseling.  
Participants 
 The study population consisted of patients admitted between January 1st 2014 and 
December 31st 2015 who were at least 18 years of age, and had a length of stay between 3 and 
120 days. These inclusion criteria conformed to CMS population parameters for TOB-1, TOB-2, 
and TOB-2a.(45) For patients with multiple admissions within a given study year, the last 
treatment episode was selected for inclusion in the study. Treatment episodes that spanned the 




 Study data was obtained from the hospital EMR and the UKanQuit service database.  
EMR data included age, gender, ethnicity, race, primary language, health insurance type, length 
of stay, discharge diagnosis, inpatient medication administration record, tobacco-use history, 
smokeless tobacco use history, documented referral for cessation counseling, and documented 
referral for cessation medication.  
 UKanQuit data included average number of cigarettes smoked per day, whether patient 
routinely smokes within 30 minutes of waking, years of tobacco use, interest in quitting (0-10 
scale, 10 equals high interest), use of smoking cessation medication in the hospital, interest in 
starting or changing cessation medication, acceptance of offer for quitline referral, and 
acceptance of offer for referral to the National Cancer Institute’s free text to quit service 
SmokeFreeTXT. (47) 
Main outcome measures: TOB-1, TOB-2, TOB-2a.  
Concurrent with the January 1, 2015 implementation of the CMS measures, KUMed 
created a number of reports and new fields within the EMR to better capture tobacco use 
screening and referral for tobacco-related counseling and medication.  These reports and fields 
were not, however, in place prior to the rule—in 2014. In order to avoid reporting bias, we 
abstracted data for TOB-1, TOB-2, and TOB-2a in exactly the same manner, from the same 
fields, in 2014 and 2015.   
For TOB-1 (screening for tobacco use), documentation was inconsistent in 2014, prior to 
measure implementation. Hence, for 2014 and 2015 we counted all smokers with any evidence in 
the EMR of screening, tobacco use, or tobacco treatment as having been “screened.” This 
included any documentation of tobacco use or treatment in the social history, any evidence of 
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cessation counseling received, and any evidence of cessation medication received. Patients with 
missing documentation were counted as not being screened, and were also counted as non-
smokers.  
Likewise, for TOB-2 (refused or received counseling/medication), documentation was 
inconsistent in 2014, prior to CMS measure implementation. There was, specifically, no field 
created until the latter part of 2014, which indicated whether a patient had been offered or 
refused counseling or medication. Hence, for 2014 and 2015 we defined TOB-2 as any evidence 
in any field of the EMR that a patient had been referred and/or received cessation counseling 
and/or cessation medications. Due to the inability to accurately assess whether bupropion was 
prescribed for cessation treatment or psychiatric treatment, bupropion was not counted as a 
cessation medication. Finally, we defined TOB-2a as any evidence in any field in the EMR that 
cessation counseling and/or that cessation medications had been received.  
Psychiatric Diagnoses 
 We grouped cases by psychiatric diagnosis, which were typically the primary discharge 
diagnosis for each case. In the rare case in which the primary discharge diagnosis was not a 
psychiatric illness, we used the first secondary diagnosis listed for the patient that qualified as a 
psychiatric illness.  
Data Analysis 
 Patient characteristics and primary outcome measures were summarized using descriptive 
and inferential statistics.  Categorical variables were summarized using frequencies, and 
continuous variables summarized using means and standard deviations. Tests for significance 
included the two-sample t-test for differences between means and Chi Square test for differences 
in proportions. Cochran-Mantel-Haenszel (48)  test was used to analyze the relationship between 
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cohort years and outcome measures after controlling for diagnoses. Breslow-Day (48) test was 
used to analyze odds ratio homogeneity between diagnostic groups. We used Version 9.4 of the 
SAS System for Windows (49) for all analyses.  
 
Results 
Study Population and Prevalence of Smoking 
There were a total of 882 admissions for the two cohort years: 292 in 2014 and 338 in 
2015. Across both years, 252 admissions were omitted based on exclusion criteria: 6 admissions 
were excluded because they began December 2013 with length of stay spanning into 2014, 159 
admissions had a length of stay  3 days, and 87 were duplicate admissions (Figure 1).   
 
Figure 1: Study Flow Diagram 
At baseline, sex, race, and insurance status were the only characteristics found to be 
statistically different between cohort years (Table 1). There was a larger proportion of African-
Americans hospitalized in 2015, and females were more predominant in 2014. There was a 
higher proportion of patients with Medicare and self-pay insurance status in 2015, while private 
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insurance status was proportionately higher in 2014. Depressive disorders and schizophrenia 
spectrum disorders were the predominant diagnoses in both years at 72.6% versus 77.9% in 2014 
and 2015, respectively. 
 




                2015 
               N=338 
 n % n % 
Demographics   
    Mean age (SD), years 44.4 16.53 42.7 14.9 
Sexa   
    Male 122 41.78 168 49.7 
    Female  170 58.22 170 50.3 
Ethnicity   
     Non-Hispanic, Latino or Spanish Origin 275 94.18 324 95.86 
     Hispanic, Latino or Spanish Origin 16 5.48 11 3.25 
     Declined   1 0.34 3 0.89 
Raceb   
    White or Caucasian 222 76.03 227 67.16 
    Black or African-American 43 14.73 71 21.01 
    Asian 3 1.03 7 2.07 
    American Indian or Alaskan Native     0 0 4 1.18 
    Declined 1 0.34 4 1.18 
    Other 23 7.87 25 7.40 
Primary language   
     English 281 96.23 325 96.15 
     Spanish 5 1.71 3 0.89 
     Other 6 2.5 10 2.95 
Primary Psychiatric Diagnosis   
     Depressive Disorders 122 41.78 164 48.52 
     Schizophrenia Spectrum & Other Psychotic  
     Disorders                                                                      
90 30.82 98 28.99 
     Bipolar and Related Disorders      28 9.59 35 10.36 
     Substance-Related and Addictive Disorders 22 7.53 18 5.33 
     Trauma-and-Stress-or-Related Disorders 11 3.77 10 2.96 
     Other 19 6.51 13 3.85 
Mean Length of stay (SD), days 9.7 9.07 9.8 8.16 
Insurance Statusc, n (%)   
     Medicare  94 32.19 124 36.69 
     Private      93 31.85 75 22.19 
     Medicaid 64 21.92 75 22.19 
     Self-Pay 35 11.99 59 17.46 
     Other 6 2.05 5 1.48 
a = 3.96, df=1, p=.0466 
b  = 11.12, df=5, p=.0491 
c = 22.07, df=4, p<.001 
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Tobacco Screening (TOB-1) and Identification of Tobacco Use 
In 2015, there was a statistically significant increase in the proportion of patients 
screened for tobacco use; 328 (97%) compared to 247 (84.6%) in 2014, 	"1, # = 630) =
30.49,  < .001. (Table 2).  Similarly, there was an increase in the number of admissions that 
screened positive for tobacco use: 149 (44%) in 2015 versus 115 (39%) in 2014, however this 
was not statistically significant,  = 1.41, $% = 1,  = .235. Among tobacco users, 5 
admissions in 2014 and 25 admissions in 2015 reported using smokeless tobacco products.  
Notably, admissions that lacked any documentation of smoking status decreased from 45 
(15.4%) in 2014 to 10 (3%) in 2015,	 = 	29.2, $% = 1,  < .001 (Table 2).  However, the 
more complete documentation was accompanied by the emergence of contradictory information 
on smoking status. In 2015, 7 (2%) admissions had one location in the EMR (such as a 
documentation flow sheet) which indicated the patient used tobacco but another field in the same 
treatment episode (such as social history) indicated the patient was a non-smoker. No admissions 
had contradictory information on smoking status in 2014. 
Referral and Receipt of Counseling and Medications (TOB-2 and TOB-2a)  
Compared to 2014, in 2015 there was a statistically significant increase in the number of 
patients referred for cessation counseling: 5 (4.3%) in 2014 and 110 (73.8%) in 2015; 
	"1, # = 264) = 127.44,  < .001 (Table 2). The proportion of all identified tobacco users 
who actually received counseling was 9 (7.8%) tobacco users in 2014 and 100 (67.1%) tobacco 
users in 2015;		"1, # = 264) = 94.12,  < .001. 
In 2015 there was also a statistically significant increase in the number of tobacco users 
referred for cessation medications. Over half (102; 68.4%) of tobacco users in 2015 were 
referred for cessation medications compared to 37 (32%) of tobacco users in 2014;		"1, # =
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264) = 34.27,  < .001  (Table 2). However, while the proportion of tobacco users who 
actually received cessation medications increased from 28 (24.3%) in 2014 to 52 (34.9%) in 
2015, this increase only approached statistical significance;		"1, # = 264) = 3.42,  =
0.064. 
In both years nicotine replacement therapy (NRT) was the only form of cessation 
medication prescribed for tobacco users while inpatients (not shown). There were several 
patients prescribed combination bupropion and NRT, but it was not possible to determine if 
bupropion was used in combination for cessation purposes, to treat primary psychiatric 
symptoms, or both.  
Table 2: Screening, Documentation, and Treatment Pre- and Post-CMS Rule 
 2014 2015 
 N=292 N=338 
Documentation, Screening, and Identification  n % n % 
     TOB-1a: Screened** 247 84.6 328 97 
     Not screened 45 15.4 10 3 
Tobacco-use among all admissions     
Yes 115 39.4 149 44.1 
     Smokeless Tobacco use  5  25  
No 132 45.2 172 50.9 
     Missing**  45 15.4 10 3 
     Contradictory information on tobacco status   0 0 7 2 
Tobacco Users  N=115 N=149 
 n % n % 
Cessation Counseling     
TOB-2b: Referred for counseling** 5 4.3 110 73.8 
Not referred for counseling  54 47 22 14.8 
Missing documentation on referral** 56 48.7 17 11.4 
TOB-2ac: Prop. of all tobacco users receiving 
counseling**  
9 7.8 100 67.1 
Prop. referred who received counseling   9 180 100 90.9 
Cessation Medications 
TOB-2b: Referred for medications** 37 32 102 68.4 
Not referred for medications 22 19 28 18.8 
Missing documentation on referral** 56 49 19 12.8 
TOB-2ac: Prop of all tobacco users receiving 
medication 
28 24.3 52 34.9 
Prop. referred who received medication* 28 75.7 52 51 
a
 Tobacco-1 measure: tobacco use screening   
b 
Tobacco-2 measure: tobacco users offered counseling/medication  
c 
Tobacco-3 measure: tobacco users provided counseling/medication 
*
 < .01, ** < .001 
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Tobacco Use Characteristics and Counseling Details Among Treated Tobacco Users 
Among tobacco users that completed cessation counseling, patients referred for 
counseling in 2014 tended to smoke more cigarettes per day, have a higher degree of nicotine 
dependence, and to have smoked for more years than patients referred in 2015 (Table 3). In both 
years patients were on average interested in quitting smoking, although patients in 2014 reported 
a higher interest in quitting, with a mean score of 8.11 on a scale of 0 (no interest) to 10 (highly 
interested). A higher proportion of patients in 2014 were interested in cessation medications at 
discharge, 5 (55.56%) vs. 44 (44.44%) in 2015 (Table 3). Patients in 2014 were also more 
interested in a referral to the state quitline, 4 (44.44%) vs. 30 (30.61%), however few in either 
year accepted a referral to the text messaging service SmokeFreeTXT(47); 0 (0%) in 2014 vs. 4 
(4.08%) in 2015 (Table 3).  
Table 3: Tobacco Use Characteristics and Treatment Received Among Inpatients Referred for 
Counseling/Medication pre-post CMS rule. 
 2014 2015 
  n % n % 
Smoking characteristics     
   Avg number of cigarettes /day  (Mean± SD)  n=9; n=98 20.56	±16.77 15.19 ±12.47 
   Use tobacco within 30 min waking  n=9; n=97                   8 88.9 70 72.2 
   Use other types of tobacco products n=9; n=96                0 0 20 20.8 
   Years of tobacco use, (Mean±SD)      n=9; n=89 27.78	±16.05 20.29 ±12.92 
   Interested in quitting; (0-10=Low-High) 
(Mean±SD)  
n=9; n=94                8.11	±2.76 
 
6.22 ±3.97 
Cessation Medication    
Currently prescribed in hospital  n=9; n=99                     6 66.7 49 49.5 
   Interested in inpatient medication /med change             n=9; n=99                     4 44.4 41 41.4 
   Interested in medication at discharge  n=9; n=99                     5 55.6 44 44.4 
       Quitline referral                                      n=9; n=98   
          Accepted   4 44.4 30 30.6 
       Smoke Free Text                                 n=9; n=98   






Screening and Treatment by Psychiatric Diagnosis  
The Cochran-Mantel-Haenszel test was used to analyze pre-post CMS rule changes in our 
primary tobacco measures after controlling for psychiatric diagnosis. In 2015, all admissions 
experienced increased odds of being screened for tobacco use (odds ratio [OR] =5.19. p<.0001). 
Similarly, in 2015, tobacco users experienced increased odds of being referred for counseling 
(odds ratio [OR] =7.26. p<.0001), receiving counseling (odds ratio [OR] =22.99. p<.0001), and 
being referred for medications (odds ratio [OR] =6.29. p<.0001). (Table 5). However, in 2015, 
tobacco users were as likely to receive medications as users in 2014 (odds ratio [OR] =1.59. 
p=.0978). The Breslow-Day test which analyzes the odds ratio homogeneity between diagnostic 
groups, did not reach the level of significance for any outcome measures. Thus, there were no 
statistically significant differences in the odds ratios for the main outcome measures between 
diagnostic groups. 
Table 4: Screening, Tobacco Use and Tobacco Treatment by Psychiatric Diagnosis. 



















  2014 2015 2014 2015 2014 2015 2014 2015 2014 2015 2014 2015 
Sreened  N 110 160 70 93 24 34 20 18 7 10 16 13 
% 90.1 97.5 77.7 94.8 85.7 97.1 90.9 100 63.6 100 84.2 100 
Tobacco 
Use 
N 55 63 35 44 10 19 12 13 1 5 2 5 
% 46.6 53.3 44.3 55.6 34.4 65.5 48.0 52.0 16.6 83.3 28.5 71.4 
Counselling 
Referred 
N 30 55 18 39 5 18 6 12 0 5 0 3 
% 54.5 87.3 51.4 88.6 50 94.7 50 92.3 0 100 0 60 
Counsleing 
Received  
N 4 40 1 30 2 15 2 8 0 5 0 3 
% 7.2 63.4 2.8 68.1 20 78.9 16.6 61.5 0 100 0 60 
Medication 
Referred 
N 30 54 18 38 5 18 6 12 0 5 0 5 
% 54.5 85.7 51.4 86.3 50 94.7 50 92.3 0 100 0 100 
Medication 
Received  
N 13 25 7 10 2 8 4 4 1 3 1 2 





Table 5: Tobacco Measures Outcomes Post-CMS Rule: Controlling for Psychiatric Diagnosis. 
 OR 95% CI p 
Screened 5.19 2.64-10.18 <.0001 
Counseling referred 7.26 3.78-13.91 <.0001 
Counseling received 22.99 10.53-50.19 <.0001 
Medications referred 6.29 3.35-11.79 <.0001 
Medications received 1.59 0.913-2.78    0.0782 
*Cochran-Mantel-Haenszel Test Controlling for Psychiatric Diagnosis 
 
Discussion  
Implementation of the CMS tobacco measures was associated with statistically 
significant increases in screening for tobacco use, referrals for cessation counseling and 
medications, and receipt of cessation counseling. However, the proportional increase observed in 
tobacco users receiving cessation medications, was not statistically significant. Gains in 
screening and treatment did not differ across psychiatric diagnoses.  The proportion of 
psychiatric inpatients that received cessation medications increased marginally from 2014 to 
2015, but the proportion of inpatients receiving cessation counseling in the hospital increased 10-
fold.  
It appears that, compared to patients receiving treatment in 2015, the 9 psychiatric 
inpatients who received treatment in 2014 were more dependent smokers with a longer smoking 
history and greater motivation to quit.   It is possible that patients who received cessation 
counseling in 2014, were referred because these patients experienced high levels of withdrawal 
symptoms.   
It is important to note that the tobacco treatment that patients received from UKanQuit in 
2015 appears less successful than the treatment received in 2014. For example, more tobacco 
users in 2014 were interested in cessation medications at discharge, as well as a referral to the 
state quitline than patients receiving the same counseling in 2015.  These percentages, however, 
16 
 
mask the overall impact.  Because the psychiatric unit adopted a population-based approach to 
tobacco treatment, the absolute number of patients receiving counseling was 10-times greater in 
2015 compared to 2014, and this translated to a much greater absolute number of patients 
receiving prescriptions for medications at discharge and referral to the state tobacco quitline. 
This illustrates the power of the proactive approach to tobacco cessation treatment that was 
adopted in 2015, compared to the reactive approach used in 2014. Instead of addressing tobacco 
cessation only among highly dependent, motivated patients, engaging all tobacco users upon 
admission increased the number of patients who actually received cessation treatment.  
The automatic referral process implemented in 2015—in which all identified tobacco 
users were referred to the hospital tobacco treatment service UKanQuit, appears to have been 
more effective in increasing cessation counseling than cessation medications.  This may also 
have been due to proactive dispensing of cessation medication to all hospitalized tobacco users. 
This practice was instituted in 2006 when the hospital campus went tobacco free and psychiatric 
inpatients were no longer allowed to step outside for smoke breaks.   
The increases in treatment delivery observed in our psychiatric unit may support the use 
of an automatic referral system to better engage patients in treatment. An automatic referral 
system results in the actual offer for cessation treatment taking place apart from the intake 
process which can be taxing to patients, especially to patients experiencing psychiatric 
symptoms, 2/3 of whom are admitted from the emergency department several hours after first 
coming in.   
Similar to other studies, we found that psychiatric inpatients were interested in quitting 
tobacco.(50, 51). After the CMS rule went into effect and large proportions of patients were 
receiving tobacco treatment, 44% expressed an interest in continuing cessation medications at 
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discharge, and nearly one in three (31%) accepted a referral to the state tobacco quitline. This 
was similar to findings by Stocking et al., (2014), who observed a 27.9% quitline participation 
rate among psychiatric smokers offered services post discharge.(52)  
There were several limitations to our study. First, we could not ascertain whether patients 
who were not referred for cessation medications had a medical contraindication or another 
reason for not being referred. Similarly, we could not determine the cause of the discrepancy 
between the high numbers of referrals for cessation medications and the small number of tobacco 
users who received cessation medications in 2015. We obtained anecdotal reports that patients 
with lower levels of nicotine dependence often decline cessation medications at delivery, 
however, we could not verify such reports through documentation in the EMR.  
Because we used only EMR fields and reports that were available across both years of the 
study, we also could not identify when screening actually occurred for patients.  That is, we do 
not report whether screening and treatment occurred within the 36-hour window set by CMS or 
even within the present treatment encounter. In 2015, documentation of smoking status changed 
to include the use of a documentation flowsheet within the EMR, complete with date and time 
“stamps” which had not been utilized by the psychiatric unit in 2014. Thus, for some patients in 
2014, information regarding smoking history came solely from the social history section of the 
EMR which could have been entered at a previous treatment encounter. If we had been able to 
obtain the date that smoking history was entered into the social history, our screening rates for 
2014 would have most likely been lower, while 2015 screening rates would have remained 
relatively unchanged.  
Despite the high prevalence and overwhelming health impacts of tobacco use in patients 
with mental illness, little has been done in the past to provide tobacco cessation treatment during 
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psychiatric hospitalization. (20) Individual performance on IPFQR measures are publicly 
available for consumers to compare quality of care given at various psychiatric facilities. This 
increased transparency allows consumers an opportunity to make informed decisions regarding 
where to seek care. 
Psychiatric hospitalization, similar to hospitalization for other medical conditions such as 
CHF, AMI, COPD and pneumonia, which currently have performance penalties associated with 
their treatment outcomes, is often needed on an emergent basis and hampers the ability of 
consumers to adequately compare health care facilities prior to seeking care.  Hospitals 
participating in public reporting and pay for performance have been shown to achieve greater 
improvements in quality than hospitals participating in public reporting alone. (53)  
Our study exemplifies the impact these new reporting measures can have when 
psychiatric facilities move beyond letter of the policy, to continually assess organizational 
performance and implement changes to improve treatment delivery.  With an estimated 1,626 
inpatient psychiatric facilities nationwide participating in the IPFQR program (46), assessing 
financial penalties based on performance, in addition to reporting, could markedly increase 
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